Skip to content

Writing About Experiences With Ovarian Cancer

Writing About Experiences With Ovarian Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02593422
Enrollment
73
Registered
2015-11-02
Start date
2015-04-30
Completion date
2016-12-31
Last updated
2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

ovarian cancer, expressive writing, writing interventions, psychosocial support

Brief summary

This online study aims to understand whether writing about one's experiences with ovarian cancer may be beneficial for psychological and physical wellbeing in women with a history of ovarian cancer. Investigators are also interested in studying how certain individual characteristics may impact the effectiveness of writing. Participants will be asked to complete an initial survey (15 min), followed by writing about their experiences with ovarian cancer on four occasions (20 - 25 min each), over the course of two weeks. A final survey (10 min) will be completed one month afterwards.

Detailed description

The purpose of this randomized controlled experiment is to examine the effects of writing about experiences with ovarian cancer on psychological and physical outcomes in English-speaking women with a history of ovarian cancer. It will also examine how certain individual characteristics may impact the effectiveness of the writing interventions for different women. After completing an initial survey, women will be asked to write about their experiences with ovarian cancer on 4 separate occasions of 20-25 min each in the course of 2 weeks. A final survey will be completed one month after the last writing session. The entire study will be conducted online.

Interventions

BEHAVIORALExpressive Writing

Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer

BEHAVIORALFact Writing (Control)

Participants will be asked to write about the facts of their experience with ovarian cancer

Sponsors

University of Maryland, College Park
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women with a history of ovarian cancer (any stage) * At least 18 years old * English-speaking/Can comfortably read and write in English * Able to provide informed consent * Internet access * Valid email address * Any region/country

Exclusion criteria

* Minors (younger than 18) * Lack of English proficiency * Inability to provide informed consent * Male

Design outcomes

Primary

MeasureTime frameDescription
Change in Psychological Functioning (Wellbeing/Distress)6 - 9 weeks, with timely completion of writing: Initial survey (day 1), after 2nd writing task (week 1), after 4th writing task (week 2), and one month after last writing task (week 6)Various aspects of social, emotional and functional wellbeing will be assessed using the Functional Assessment of Cancer-Ovarian measure (FACT-O, Version 4, Basen-Engquist et al, 2001). Distress about ovarian cancer will be assessed using the Impact of Event Scale (IES, Horowitz, Wilner & Alvarez, 1979).

Secondary

MeasureTime frameDescription
Change in Physical Wellbeing6 - 9 weeks, with timely completion of writing: Initial survey (day 1), after 2nd writing task (week 1), after 4th writing task (week 2), and one month after last writing task (week 6)Physical symptoms and concerns specific to ovarian cancer will be assessed using Functional Assessment of Cancer - Ovarian (FACT-O, Version 4, Basen-Engquist et al, 2001).
Changes in affect before and after writing about ovarian cancerPrior to and after each of 4 writing tasks (weeks 1 - 2)Positive and negative affect will be assessed using the Positive and Negative Affect Scale (PANAS, Watson, Clark & Tellegen, 1988).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026